Altimmune, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed on September 24, 2018, by Altimmune, Inc., a Delaware corporation. The report details a material definitive agreement entered into on September 20, 2018, involving the Biomedical Advanced Research and Development Authority (BARDA).
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, or debt metrics. The only specific financial figures disclosed relate to the contract modification:
- Contract Modification Amount: $2.5 million added to the base contract.
- Modified Base Contract Total: $24.1 million (up from $21.6 million).
- Extended Performance Period: Through November 2019.
- Total Potential Funding: If all options are exercised, the NasoShield program contract (HHSO100201600008C) could total up to $105 million, extending through the end of Phase 2 development (September 2021).
Material Changes
The primary material change is the expansion of the existing BARDA contract to support the NasoShield vaccine program. The additional $2.5 million is designated for:
- Vaccine characterization, including key formulation parameters and batch consistency.
- Assaying clinical samples from the ongoing Phase 1 trial for mucosal immune response.
- Comparing different methods of intranasal administration in preclinical models.
Outlook and Management Commentary
Management expects immunogenicity data for the two-dose cohort to be available in the fourth quarter of 2018. The funding extension supports the progression of the NasoShield program toward Phase 2 development. No specific risks or contingencies were detailed in this specific filing beyond the standard nature of clinical development.
Key Facts for Investor Verification
- Verify the specific milestones required to exercise the remaining options to reach the potential $105 million total funding.
- Monitor the release of immunogenicity data for the two-dose cohort expected in Q4 2018.
- Confirm the status of the Phase 1 clinical trial and the timeline for transitioning to Phase 2.
- Review the full text of the press release (Exhibit 99.1) for additional details on the BARDA agreement.